Clinical significance of IGF1R expression in nonsmall-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 2, 2012, Pages 136-142

  Nakagawa, Makoto ^a   Uramoto, Hidetaka ^a   Oka, Soichi ^a   Chikaishi, Yasuhiro ^a   Iwanami, Takashi ^a   Shimokawa, Hidehiko ^a   So, Tomoko ^a   Hanagiri, Takeshi ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

IGF1R; Ki 67; Lung cancer; Nonsmall cell Lung Cancer; Recurrence

Indexed keywords

KI 67 ANTIGEN; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, IGF TYPE 1; SURVIVAL RATE;

EID: 84857383814     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.10.006     Document Type: Article

References (36)

1. J. Ferlay, H.R. Shin, F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. T. Hanagiri, T. Baba, T. So Time trends of surgical outcome in patients with non-small cell lung cancer J Thorac Oncol 5 2010 825 829
3. T. Goya, H. Asamura, H. Yoshimura The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study Lung Cancer 50 2005 227 234 (Pubitemid 41427898)
4. J.P. Pignon, H. Tribodet, G.V. Scagliotti Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
5. H. Kato, Y. Ichinose, M. Ohta Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 2004 1713 1721 (Pubitemid 38501140)
6. H. Shimokawa, H. Uramoto, T. Onitsuka TS expression predicts postoperative recurrence in adenocarcinoma of the lung Lung Cancer 72 2011 360 364
7. G. Chundong, H. Uramoto, T. Onitsuka Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis Anticancer Res 31 2011 1141 1145
8. H.M. Khandwala, I.E. McCutcheon, A. Flyvbjerg The effects of insulin-like growth factors on tumorigenesis and neoplastic growth Endocr Rev 21 2000 215 244 (Pubitemid 32275588)
9. D. LeRoith, C.T. Roberts Jr The insulin-like growth factor system and cancer Cancer Lett 195 2003 127 137 (Pubitemid 36588961)
10. H. Uramoto, T. Iwata, T. Onitsuka Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma Anticancer Res 30 2010 2513 2517
11. Shimokawa H, Uramoto H, Tanaka F. Comment on "Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab." Br J Cancer 105:1465-6.
12. S. Thomson, F. Petti, I. Sujka-Kwok A systems view of epithelial-mesenchymal transition signaling states Clin Exp Metastasis 28 2011 137 155
13. R. Sivakumar, H. Koga, K. Selvendiran Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition Int J Oncol 34 2009 329 338
14. N.A. Said, E.D. Williams Growth factors in induction of epithelial-mesenchymal transition and metastasis Cells Tissues Organs 193 2011 85 97
15. M. Nakagawa, H. Uramoto, H. Shimokawa Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung Exp Ther Med 2 2011 585 590
16. E. Vallires, F.A. Shepherd, J. Crowley International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer J Thorac Oncol 4 2009 1049 1059
17. M. Sugaya, H. Uramoto, A. Uchiyama Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer Anticancer Res 30 2010 3039 3044
18. H. Uramoto, R. Nakanishi, A. Nagashima A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer Anticancer Res 30 2010 4695 4699
19. T. Onitsuka, H. Uramoto, N. Nose Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status Lung Cancer 68 2010 198 203
20. T. Yamashita, H. Uramoto, T. Onitsuka Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC Lung Cancer 70 2010 320 328
21. M.H. Chang, J. Lee, J. Han Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer APMIS 117 2009 861 869
22. H. Uramoto, S. Yamada, T. Hanagiri Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung Anticancer Res 30 2010 4717 4720
23. T. Onitsuka, H. Uramoto, K. Ono Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status J Thorac Oncol 5 2010 591 596
24. J. Celis, R. Bravo, R. Larsen A nuclear protein whose level correlates with the proliferative state of normal as well as transformed cells Leuk Res 8 1984 143 147
25. Y. Gong, E. Yao, R. Shen High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507) PLoS One 4 2009 e7273
26. V. Ludovini, G. Bellezza, L. Pistola High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients Ann Oncol 20 2009 842 849
27. R. Dziadziuszko, D.T. Merrick, S.E. Witta Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression J Clin Oncol 28 2010 2174 2180
28. A. Gualberto, M. Dolled-Filhart, M. Gustavson Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition Clin Cancer Res 16 2010 4654 4665
29. F. Cappuzzo, G. Tallini, G. Finocchiaro Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients Ann Oncol 21 2010 562 567
30. C. Desbois-Mouthon, D. Wendum, A. Cadoret Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout FASEB J 20 2006 773 775 (Pubitemid 46671211)
31. D.T. Merrick, R. Dziadziuszko, B. Szostakiewicz High insulin-like growth factor 1 receptor (IGF 1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients J Clin Oncol 25 suppl 2007 abstract 7550 www.asco.org Accessed: October 28, 2011
32. A. Gualberto, M. Pollak Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions Oncogene 28 2009 3009 3021
33. J. Rodon, V. DeSantos, R.J. Ferry Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials Mol Cancer Ther 7 2008 2575 2588
34. S.J. Weroha, P. Haluska IGF-I receptor inhibitors in clinical trialsearly lessons J Mammary Gland Biol Neoplasia 13 2008 471 483
35. D.D. Karp, L.G. Paz-Ares, S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 2009 2516 2522
36. J. Jassem, C.J. Langer, D.D. Karp Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 suppl 2010 abstract 7500 www.asco.org Accessed: October 28, 2011